60 mg matching 120 mg signals scalable NLRP3 inflammation play

A lower daily dose hit the same inflammation drop as a higher one, which is the kind of Phase 1 signal drug developers want before scaling. BioAge's BGE-102, an oral NLRP3 inhibitor aimed at cardiovascular risk, showed its new 60 mg once-daily cohort matching the earlier 120 mg results in obese participants with high baseline inflammation.

At 60 mg, median hsCRP fell 85% by day 7 and 86% by day 21; the 120 mg dose showed an 86% reduction at day 14. The drug was reported as well tolerated with no serious adverse events, and also reduced IL-6 and fibrinogen, reinforcing the core idea: suppressing NLRP3-driven inflammation as a preventive cardiovascular strategy.